Abstract

Background: Ulcerative colitis (UC) is an inflammatory bowel disease with conflicting evidence from studies on the roles of TNFα, IL-8, TGFβ and other cytokines and characterised by neutrophil infiltration and tissue destruction.

Aim: To compare cytokine profiles of inflamed and non-inflamed mucosa in patients with distal UC, and matched controls.

Methods: Patients were prospectively recruited, mucosal biopsies at flexible sigmoidoscopy (FS) were taken from UC patients within macroscopically inflamed and non-inflamed proximal mucosa, and from age–sex matched controls undergoing FS. Endoscopic and histological inflammation was graded. Quantitative cytokine analysis for IL-4, TNFα, IL-17A, IL-8, IL-10, TGFβ and IFNγ was carried out on tissue homogenates. Statistical comparison was by Wilcoxon signed rank pair analysis, Mann–Whitney U test and Spearman's correlation.

Results: 69 active UC patients (54 paired non-inflamed/inflamed mucosa) and 69 controls were compared. In inflamed mucosa, elevation in IL-8 and reduction in TGFβ was measured compared with non-inflamed mucosa (p < 0.001; p < 0.02) and control mucosa (p < 0.001; p < 0.001); IL-8 was positively correlated (rs = 0.481, p < 0.01) and TGFβ inversely correlated (rs = 0.462; p < 0.01) with grade of inflammation. TNFα concentration was not significantly different. Comparisons of inflamed with non-inflamed mucosa also demonstrate significant reduction in concentration of IFNγ (p < 0.001), IL-4 (p < 0.005) and IL-17A (p < 0.002).

Conclusion: Our findings suggest that IL-8 is elevated and TGFβ is reduced in distal colitis. Lower concentration of IFNγ, IL-4 and IL-17A were also noted. TNFα levels were unchanged. These findings suggest that the inflammatory response in UC may predominantly involve IL-8 mediated neutrophil infiltration and failure of TGFβ mediated tissue healing.

Introduction

Ulcerative colitis (UC) is a chronic, relapsing intestinal inflammatory disorder of the colon, with variable distribution but limited to the distal bowel (distal colitis and proctitis) in 60% of cases.1 UC has an unconfirmed but likely multifactorial aetiology that may reflect either a primary immunological dysfunction or an inappropriate and pathological immunological response to an environmental factor, e.g. commensal intestinal microorganisms.2 Mucosal inflammation in UC is characterised by an infiltrate of plasma cells, eosinophils and neutrophils which correlate with disease severity.3,4

In distal UC, there often exists a clear demarcation between actively inflamed distal mucosa and apparently normal proximal mucosa. This demarcation is often well preserved and may persist for years; however, occasionally the disease will extend or regress. The pathogenesis of this clinical presentation remains poorly defined but suggests localised dysregulation of the inflammatory response.

Current pharmacological interventions in UC demonstrate variable efficacy in disease control with approximately half of cases associated with chronic active or intermittent symptoms or requiring colectomy, leading to a significant impact on patient lifestyle.5 Immunologically targeted interventions including anti-tumour necrosis factor-α (TNFα) antibodies68 have demonstrated clinical efficacy in UC patients with moderate to severe disease, including in distal colitis. This suggests a contributory role of cytokines towards activation of the inflammatory cascade in UC and their value as a potential therapeutic target; however, there may be alternative immunopharmacological targets in this group of patients.

However, there remains uncertainty over the comparative profiles of different cytokine families during the mucosal inflammatory response, with conflicting results of published studies. Reports from experimental animal models and human IBD colonic resection suggest that UC represents a non-classical TH2 response9 characterised by the release of interleukin (IL)-4, 5 that contrasts with the proposed Th1/Th17 cell response characteristic of Crohn's disease associated with production of interferon-γ (IFN-γ), IL-12, IL-17 and IL-23.10 However, comparative studies of cytokine profiles in patients with active disease and compared to healthy controls11,12 suggest a mixed or even predominantly Th1 immunophenotype. Furthermore, there is also evidence to suggest involvement of inappropriate mediator release by T-regulatory (Treg) cells.13 This has limited our understanding of the relationship of cytokine expression to mucosal inflammation, which is necessary for the introduction of new cytokine modifying strategies.

A number of factors may have contributed to the inconsistent findings in the published literature, including the natural heterogeneity of baseline cytokine profiles14 confounding comparison between subjects, and the influence of patient characteristics including drug regimens, or epidemiological factors. We hypothesised that comparing cytokine concentration above and below the demarcation line in between endoscopically active and healthy colonic mucosa in active UC patients would reduce the influence of such confounding factors and allow an examination of the relationship between cytokine profiles and mucosal inflammation.

Materials and methods

Subjects and study design

This was a prospective case-controlled study of UC patients and age and sex-matched healthy controls. Patients were identified during attendance at gastroenterology outpatient clinics at the Royal Haslar and St Mary's Hospital, Portsmouth Hospitals NHS Trust between November 2008 and July 2009. The diagnosis of UC was based on endoscopic and histological investigation.15,16 All recruited patients underwent a questionnaire based assessment of their demographic characteristics, previous and presenting medical history, and UC history. Clinical disease activity was determined using the UCDAI score.17

Patients with clinical evidence of active disease underwent unprepared flexible sigmoidoscopy examination as part of their routine clinical management. An endoscopy assessment was undertaken by two endoscopists blinded to the patient's clinical presentation using a scoring tool (Sutherland et al.)16 to stratify patients into active or quiescent UC, or normal mucosa and with photographic evidence obtained. Flexible sigmoidoscopy in patients with active distal UC was followed by grab biopsy in inflamed and non-inflamed mucosa proximal to demarcation between inflamed and non-inflamed mucosa. Biopsies were taken using flexible biopsy forceps according to standard protocol.

A control group of age–sex matched patients undergoing unprepared flexible sigmoidoscopy for other clinical indications but without presenting or previous medical history suggestive of UC were recruited, and with subsequent confirmation of histologically normal colonic mucosa entered into the study as control subjects. Random biopsies were taken and stored as above as external controls.

Exclusion criteria included patients: aged less than 16 or greater than 80 years of age; those declining endoscopic evaluation; with a presumptive diagnosis of Crohn's, infective or ischaemic colitis; with concurrent use of non-steroidal anti-inflammatory medication or inability to provide consent.

Sample preparation

Mucosal biopsy samples taken at the time of endoscopy were uniquely identified, and snap frozen in liquid nitrogen. Homogenisation buffer (500 μl) containing phosphate buffer saline (PBS) (Invitrogen, Paisley, UK) without Ca2 +/Mg2 +, detergent (1% Triton X-100 (TX-100) (Sigma-Aldrich, St Louis, USA) and containing double strength protease inhibitor (Calbiochem, USA) was added following thawing and weighing, with homogenisation on ice (13,500 rpm, 15-second gap in between two 15-second bursts) (Ultra-turrax T25-Janke & Kunkel, IVA labortechnik) followed by centrifugation (5 minutes at 13,000 rpm) (Jensons MIKRO 22R). The supernatant was then stored at − 80 °C until analysis.

Cytokine ELISA analysis

Cytokines were analysed using ELISA kits as per manufacturer's instructions (Peprotech EC, London, UK) for IL-4, TNFα, IFNγ, IL-8, IL-17A, IL-10 and TGFβ. O-phenylene diamine substrate (OPD) (Sigma-Aldrich, St Louis, USA) containing 0.01 g OPD + 25 ml PBS with Ca2 +/Mg2 + + 40 μl H2O2(30%) was added, followed by 100 μl of 2 M H2SO4 (Fischer-Scientific, Leicestershire, UK) prior to plate reading using a Dynex Technology plate reader at 490 nm.

BCA total protein assay (Pierce assay)

An Albumin standard (2.0 mg/ml) calibration curve was constructed through serial dilutions (1 × PBS [without Ca2 +/Mg2 +]). A working reagent (WR) was prepared by admixture of BCA reagent A (20 ml) and B (0.4 ml). 25 μl of standard and sample in duplicate were added to each microplate well, followed by the addition of 200 μl of working reagent, mixing and incubation at 37 °C for 30 minutes, prior to plate reading using a Dynex Technology plate reader at 570 nm.

Histological analysis

Assessment of paraffin embedded serial haematoxylin and eosin (H&E) stained sections was by a histopathologist blinded to patients' identities including clinical data and using a validated histopathological scoring tool (Gomes et al.).15

Statistical analysis

Formal statistical assistance was obtained; SPSS 18 (SPSS Inc., Chicago, IL) was used for data input and analysis. Cytokine assay results were analysed adjusted for protein content.18 Units are pg/mcg protein except TGFβ (fg/mcg protein). Comparisons of cytokine concentrations in active UC patients were expressed as ratios within inflamed compared with non-inflamed mucosa, values above 1 indicate higher cytokine concentration in inflamed mucosa.

Values are quoted as median ± inter-quartile range for non-parametric data. The primary outcome variables were analysed using Wilcoxon signed rank pair analysis and Mann–Whitney U test for non-parametric variables. Correlations were tested using Spearman's rank correlation. To allow for multiple testing, a significance level of 0.01 was chosen to indicate significance.

Ethical considerations

The study was approved by the Isle of Wight, Portsmouth and South East Hampshire research ethics committee (project number 08/H0501/82). All subjects recruited to the study provided informed consent.

Results

Subjects

Patients with active UC (n = 69) were recruited with age–sex matched control subjects. Biopsy data sets of ‘paired’ macroscopically inflamed and non-inflamed tissues were available in 54 UC patients. Baseline characteristics of patients and controls are shown (Table 1). Control subjects (n = 69) presented with IBS (n = 32), rectal polyps (n = 4), diverticular disease (n = 5), haemorrhoids (n = 4), other non-inflammatory presentations (n = 5), and normal (n = 15).

Consistency of endoscopic and histological evaluation

Biopsy specimens (n = 54) within endoscopically determined non-inflamed mucosa were scored histologically. Normal histology was described (n = 38) in 74%. Microscopic inflammation was evident (n = 14) in 26%, of which mild oedema and inflammation in lamina propria (n = 13) was the predominant histological appearance.

Cytokine mucosal profiles

Comparison of mucosal concentrations of cytokines from inflamed and non-inflamed mucosa from UC patients (n = 54) are shown (Table 2). Mucosal concentration of IL-8 was significantly increased and each of TGFβ, IFNγ, IL-4 and IL-17 were significantly reduced in inflamed compared with non-inflamed mucosa. There were no differences in concentrations of TNFα.

Comparison of cytokine profiles in inflamed mucosa from UC patients (n = 69) and from age–sex matched controls (n = 69) is shown (Table 3). Concentration of IL-8 was significantly increased and TGFβ and IFNγ significantly reduced in inflamed mucosa. There were no differences in concentrations of TNFα, IL-4, IL-17 and IL-10.

There were no significant differences in mucosal concentration of IFNγ, IL-4, IL-8, IL-17, TNFα, IL-10 and TGFβ in non-inflamed mucosa from active UC patients compared with age–sex matched controls adjusted for protein (Table 4).

Correlations of cytokine concentration with endoscopic disease activity

Cytokine concentrations in inflamed mucosa were correlated against endoscopic score (Table 5, Figs. 1 and 2). Mucosal concentration of IL-8 (rs = + 0.481, p < 0.01) was significantly and positively correlated with endoscopic score. By comparison IFNγ (rs = − 0.321, p < 0.01) and TGFβ (rs = − 0.462, p < 0.01) were each significantly and negatively correlated. Mucosal concentration of TNFα, IL-4, IL-10 and IL-17 did not correlate with endoscopic activity.

Correlations of cytokine concentration with histological disease activity

Cytokine concentrations in inflamed mucosa were correlated against histological score (Table 6, Figs. 3 and 4). Mucosal concentration of IL-8 (rs = + 0.460, p < 0.01) was significantly and positively correlated with histological score. By comparison, IFNγ (rs = − 0.241, p < 0.05) and TGFβ (rs = − 0.460, p < 0.01) were each significantly and negatively correlated. Mucosal concentration of TNFα, IL-4, IL-10 and IL-17 did not correlate with histological activity.

Corticosteroid and 5-ASA subgroup analysis

Subgroup analysis of 18 patients (age 45.3; M = 10 [55%], F = 8 [45%]) not on 5-ASA or corticosteroid treatment compared to 67 age–sex matched control group, was carried out (Table 7). Only 2 (11.1%) patients were receiving maintenance therapy (azathioprine). Extent of colitis (Proctitis 12 [66.7%], sigmoiditis 5 [27.8%], left sided 1 [5.5%], extensive 0 [0%]), endoscopic severity (1:13 [72.2%]; 2:3 [16.7%]; 3:2 [11.1%]) and histological severity (0:3 [16.7%]; 1:7 [38.9%]; 2:6 [33.3%]; 3:2 [11.1%]; 4:0 [0%]) were similar to the full group of 54 (Table 1).

Concentration of IL-8 was significantly increased and TGFβ significantly reduced in inflamed mucosa; however no difference in IFNγ was noted. Cytokine concentration was correlated with endoscopic score. Mucosal concentration of IL-8 (rs = + 0.333, p < 0.01) was significantly and positively correlated and TGFβ (rs = − 0.373, p < 0.01) was significantly and negatively correlated. By comparison, IFNγ, TNFα, IL-4, IL-10 and IL-17 did not correlate with disease activity.

High endoscopic and histological severity subgroup analysis

Subgroup analysis of 12 patients (age 38; M = 9 [75%], F = 3 [25%]) with high endoscopic score (grade 3, [Table 8]) and 10 patients (age 36.5; M = 6 [60%], F = 4 [40%] with high histological score (grade 4, [Table 9]) compared to controls was carried out. Mucosal IL-8 concentration was significantly increased in the severe subgroup measured endoscopically and histologically (p < 0.001); conversely, mucosal TGFβ concentration was significantly reduced in the severe subgroup measured endoscopically (p < 0.001) and histologically (p < 0.01). Mucosal IFNγ concentration was also significantly reduced in the severe subgroup measured endoscopically, with a non-significant trend towards reduced concentration in the severe subgroup measured histologically (p = 0.1). By comparison TNFα, IL-4, IL-10 and IL-17 did not correlate with disease activity.

Discussion

The results of this study suggest that colonic mucosa in active distal UC is associated with contrasting mucosal cytokine production in inflamed compared to non-inflamed mucosa proximal to the inflammatory demarcation line in the same patient, and to external matched controls; the pattern indicates elevated concentrations of IL-8 and reduced concentrations of TGFβ in inflamed mucosa. Furthermore IL-8 concentration is significantly positively correlated with endoscopically and histologically determined disease activity, in contrast TGFβ is significantly inversely correlated with the same. Finally, these contrasting findings are consistent in the subgroup analyses.

This is the first time that the inverse relationship between TGFβ concentration and disease activity has been documented; in addition, it is the first time that IL-8 concentration has been demonstrated to correlate positively with validated endoscopic and histological scoring systems in the same model. These findings are consistent in the subgroup not on 5-ASA or corticosteroids, which demonstrates that they are not related to therapeutics.

The results also suggest a significantly lower concentration of IFNγ, IL-4, IL-17, and IL-10 (non-significant trend), but not TNFα, in inflamed compared to non-inflamed mucosa from UC patients. TNFα and the other measured cytokines did not demonstrate a consistent correlation with disease activity. Finally, there did not appear to be significant differences between non-inflamed mucosa from UC patients and controls.

Histological evaluation of endoscopically determined non-inflamed mucosa (in patients with active colitis) confirmed the absence of a microscopic inflammatory infiltrate in 74% of samples, and demonstrated a minor inflammatory infiltrate in all but 1 (2%) of the remainder. This finding and the failure to detect a difference between cytokine profile in endoscopically determined non-inflamed mucosa and matched controls, justified endoscopic assessment as a tool to delineate inflamed from non-inflamed mucosa.

Previous investigators have examined cytokine profiles in UC, both in serum and mucosa, examining a wide array of cytokines. The results are frequently contradictory which may reflect differences in study design, sample size or scientific methodology. The current study is the largest cohort study of mucosal cytokine expression in UC; the scientific methodology included quantitative cytokine measurement, not mRNA production (a surrogate marker of cytokine production).

Our results are consistent with an association between IL-8 mucosal concentrations and mucosal inflammation in UC. This cytokine, commonly associated with the innate immune response, has a recognised chemoattractant effect on neutrophils.19 Raised IL-8 concentrations have been demonstrated in previously published studies of active UC2024, are known to be associated with disease activity21,25 and are considered to be an independent prognostic indicator of risk of future relapse in quiescent colitis.26

By comparison, TGFβ, which is a pleiotropic cytokine and an inhibitor of Th1, Th2 differentiation, NK cell activity2729 and is involved in tissue repair, is reduced in inflamed mucosa in our study; this is a novel finding. Experimental studies using cyclosporine (a potent anti inflammatory drug used in patients with fulminant steroid resistant UC30) demonstrate cyclosporine induced TGFβ-mediated inhibition of epithelial apoptosis, reversed by addition of anti-TGFβ antibodies.31 Previous studies with transgenic mice expressing mutant TGFβ receptors demonstrate increased susceptibility to spontaneous colitis, DSS (dextran sodium sulphate) colitis and with delay in healing when TGFβ signalling is interrupted.32,33 This suggests TGFβ is central in the maintenance of intestinal homeostasis and repair.

Significantly lower concentrations of the cytokines IL-4, IL-17 and IFNγ (with a trend towards a lower level of IL-10) may represent a down-regulation of the respective immune cell types. IL-17 upregulation, reflecting Th17 cell activation, stimulates cytokines TNFα and IL-8 as part of the adaptive immune response3436 and IFNγ reflects Th1 cell activation (as commonly seen in Crohn's disease37). IL-4, reflecting Th2 cell activation, is elevated in inflamed UC mucosa in some studies while in others it is normal or downregulated.38

The failure to note a difference in TNFα level, a ubiquitous cytokine, is disappointing and conflicts with published experimental and clinical studies demonstrating elevated TNFα in active UC and clinical efficacy of anti-TNFα antibodies respectively.23,3941 However, subgroup analysis in published studies suggests significant differences between TNFα mRNA in severely inflamed compared with mild-moderately inflamed mucosa in UC which may reflect a switch to a TNFα phenotype during the inflammatory process.41 It is possible that TNFα-mediated inflammation becomes apparent in severe disease (explaining the response to anti-TNFα biologic agents) that was not well represented in our patient cohort (17% of study acute colitis patients).

In this study, we have used patients as their own controls, and with non-related age–sex matched controls, and have demonstrated reproducibility in the major results. Comparisons of cytokine production between individuals may be confounded by genetic polymorphism in cytokine production,42 drug therapy, environmental factors, amongst other factors. Our methodology attempted to control for such factors by providing internal comparisons using non-inflamed tissue adjacent to colitis samples in patients.

The clinical significance of these results is that IL-8 and TGFβ production seem to be intimately and consistently related to the severity of the inflammatory response measured in vivo, whereas TNFα, IL-4, IFNγ, IL-17A and IL-10 do not consistently demonstrate close association. Both elevated IL-8 and reduced TGFβ may be fundamentally important in the loss of intestinal homeostasis which develops in UC; the clinical significance of the other measured cytokines may become more apparent in more severe disease states.

In conclusion, the results of this study suggest a major role for IL-8 mediated neutrophil infiltration, seen histologically, and failure of TGFβ mediated maintenance of intestinal homeostasis and tissue healing. This is consistent with the hypothesis that the primary driver of the inflammatory response in distal UC (at least in mild to moderate disease) is the innate immune response. Furthermore, inflammation in these patients appears to be limited to the area of colitis, supporting the use of topical in addition to systemic treatment. Finally, the cytokine profile suggests that IL-8 and TGFβ may be considered as potential targets for therapeutic intervention; the role of the other measured cytokines is less clear, and may represent a consequence rather than a direct cause of the pathophysiology of UC.

Funding

Salary and research bursary provided by Portsmouth Hospitals NHS Trust and University of Portsmouth, Portsmouth, UK.

Competing interests

None.

Contributors

Study design: DSP, TMT, MAW, JFB, JKS. Patient recruitment: DSP, TMT. Data collection: DSP, TMT, KS, MAW, HNS. Data analysis and interpretation: DSP, TMT, KS, MAW, JFB, JKS. Manuscript drafting: DSP, TMT, JFB, JKS.

Data sharing

Data sharing not available at this time due to unpublished source data. However, data sharing may be available at later date.

MESH terms: Colitis, Ulcerative, Tumour Necrosis Factor-alpha, Transforming Growth Factor beta, Interleukin-8, Interferon-gamma.
☆☆
Conference presentation: British Society of Gastroenterology annual meeting March 2011; Digestive Disease Federation June 2012.

Acknowledgements

Professor Anoop Chauhan (Director of Research, Portsmouth Hospitals NHS Trust), for support and mentorship. Endoscopy staff and study participants.

References

1
Stonnington
C.M.
Phillips
S.F.
Melton
L.J.
III
Zinsmeister
A.R.
Chronic ulcerative colitis: incidence and prevalence in a community
Gut
 
28
1987
402
409
2
Strober
W.
Fuss
I.
Mannon
P.
The fundamental basis of inflammatory bowel disease
J Clin Invest
 
117
2007
514
521
3
Geboes
K.
Riddell
R.
Ost
A.
Jensfelt
B.
Persson
T.
Lofberg
R.
A reproducible grading scale for histological assessment of inflammation in ulcerative colitis
Gut
 
47
2000
404
409
4
Geboes
J.K.
Histopathology of Crohn's disease and ulcerative colitis
Satsangi
J.
Sutherland
L.R.
Colombel
J.F.
Fiocci
C.
Lofberg
R.
Pemberton
J.
Rutgeerts
P.
Inflammatory Bowel Disease
 
2003
Churchill Livingstone
Edinburgh, London, Melbourne
255
276
5
Ochsenkuhn
T.
D'Haens
G.
Current misunderstandings in the management of ulcerative colitis
Gut
 
60
2011
1294
1299
6
Rutgeerts
P.
Sandborn
W.J.
Feagan
B.G.
Reinisch
W.
Olson
A.
Johanns
J.
et al
Infliximab for induction and maintenance therapy for ulcerative colitis
N Engl J Med
 
353
2005
2462
2476
7
Huang
X.
Lv
B.
Jin
H.F.
Zhang
S.
A meta-analysis of the therapeutic effects of tumor necrosis factor-alpha blockers on ulcerative colitis
Eur J Clin Pharmacol
 
67
2011
759
766
8
Filippi
J.
Allen
P.B.
Hebuterne
X.
Peyrin-Biroulet
L.
Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review
Curr Drug Targets
 
2011
9
Fuss
I.J.
Heller
F.
Boirivant
M.
Leon
F.
Yoshida
M.
Fichtner-Feigl
S.
et al
Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis
J Clin Invest
 
113
2004
1490
1497
10
Strober
W.
Fuss
I.J.
Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases
Gastroenterology
 
140
2011
1756
1767
11
Masuda
H.
Iwai
S.
Tanaka
T.
Hayakawa
S.
Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase
J Clin Lab Immunol
 
46
1995
111
123
12
Inoue
S.
Matsumoto
T.
Iida
M.
Mizuno
M.
Kuroki
F.
Hoshika
K.
et al
Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity
Am J Gastroenterol
 
94
1999
2441
2446
13
Coombes
J.L.
Maloy
K.J.
Control of intestinal homeostasis by regulatory T cells and dendritic cells
Semin Immunol
 
19
2007
116
126
14
Yaqoob
P.
Newsholme
E.A.
Calder
P.C.
Comparison of cytokine production in cultures of whole human blood and purified mononuclear cells
Cytokine
 
11
1999
600
605
15
Gomes
P.
du
B.C.
Smith
C.L.
Holdstock
G.
Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease
Gut
 
27
1986
92
95
16
D'Haens
G.
Sandborn
W.J.
Feagan
B.G.
Geboes
K.
Hanauer
S.B.
Irvine
E.J.
et al
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
Gastroenterology
 
132
2007
763
786
17
Sutherland
L.R.
Martin
F.
Greer
S.
Robinson
M.
Greenberger
N.
Saibil
F.
et al
5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis
Gastroenterology
 
92
1987
1894
1898
18
Andus
T.
Daig
R.
Vogl
D.
Aschenbrenner
E.
Lock
G.
Hollerbach
S.
et al
Imbalance of the interleukin 1 system in colonic mucosa—association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2
Gut
 
41
1997
651
657
19
Baggiolini
M.
Walz
A.
Kunkel
S.L.
Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils
J Clin Invest
 
84
1989
1045
1049
20
Carty
E.
De
B.M.
Feakins
R.M.
Rampton
D.S.
Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper
Gut
 
46
2000
487
492
21
Daig
R.
Andus
T.
Aschenbrenner
E.
Falk
W.
Scholmerich
J.
Gross
V.
Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease
Gut
 
38
1996
216
222
22
Ina
K.
Kusugami
K.
Yamaguchi
T.
Imada
A.
Hosokawa
T.
Ohsuga
M.
et al
Mucosal interleukin-8 is involved in neutrophil migration and binding to extracellular matrix in inflammatory bowel disease
Am J Gastroenterol
 
92
1997
1342
1346
23
Matsuda
R.
Koide
T.
Tokoro
C.
Yamamoto
T.
Godai
T.
Morohashi
T.
et al
Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naive ulcerative colitis during active and quiescent disease
Inflamm Bowel Dis
 
15
2009
328
334
24
Mazzucchelli
L.
Hauser
C.
Zgraggen
K.
Wagner
H.
Hess
M.
Laissue
J.A.
et al
Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation
Am J Pathol
 
144
1994
997
1007
25
Geboes
K.
What histologic features best differentiate Crohn's disease from ulcerative colitis?
Inflamm Bowel Dis
 
14
Suppl. 2
2008
S168
S169
26
Yamamoto
T.
Umegae
S.
Kitagawa
T.
Matsumoto
K.
Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot study
Inflamm Bowel Dis
 
11
2005
589
596
27
Gorelik
L.
Flavell
R.A.
Transforming growth factor-beta in T-cell biology
Nat Rev Immunol
 
2
2002
46
53
28
Ohtsuka
Y.
Sanderson
I.R.
Transforming growth factor-beta: an important cytokine in the mucosal immune response
Curr Opin Gastroenterol
 
16
2000
541
545
29
Ghiringhelli
F.
Menard
C.
Terme
M.
Flament
C.
Taieb
J.
Chaput
N.
et al
CD4+CD25 + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner
J Exp Med
 
202
2005
1075
1085
30
Lichtiger
S.
Present
D.H.
Kornbluth
A.
Gelernt
I.
Bauer
J.
Galler
G.
et al
Cyclosporine in severe ulcerative colitis refractory to steroid therapy
N Engl J Med
 
330
1994
1841
1845
31
Satoh
Y.
Ishiguro
Y.
Sakuraba
H.
Kawaguchi
S.
Hiraga
H.
Fukuda
S.
et al
Cyclosporine regulates intestinal epithelial apoptosis via TGF-beta-related signaling
Am J Physiol Gastrointest Liver Physiol
 
297
2009
G514
G519
32
Beck
P.L.
Rosenberg
I.M.
Xavier
R.J.
Koh
T.
Wong
J.F.
Podolsky
D.K.
Transforming growth factor-beta mediates intestinal healing and susceptibility to injury in vitro and in vivo through epithelial cells
Am J Pathol
 
162
2003
597
608
34
Hahm
K.B.
Im
Y.H.
Parks
T.W.
Park
S.H.
Markowitz
S.
Jung
H.Y.
et al
Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease
Gut
 
49
2001
190
198
34
Wuyts
W.A.
Vanaudenaerde
B.M.
Dupont
L.J.
Van Raemdonck
D.E.
Demedts
M.G.
Verleden
G.M.
Interleukin-17-induced interleukin-8 release in human airway smooth muscle cells: role for mitogen-activated kinases and nuclear factor-kappaB
J Heart Lung Transplant
 
24
2005
875
881
35
Lee
J.W.
Wang
P.
Kattah
M.G.
Youssef
S.
Steinman
L.
DeFea
K.
et al
Differential regulation of chemokines by IL-17 in colonic epithelial cells
J Immunol
 
181
2008
6536
6545
36
Jovanovic
D.V.
Di Battista
J.A.
Martel-Pelletier
J.
Jolicoeur
F.C.
He
Y.
Zhang
M.
et al
IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages
J Immunol
 
160
1998
3513
3521
37
Shih
D.Q.
Targan
S.R.
Immunopathogenesis of inflammatory bowel disease
World J Gastroenterol
 
14
2008
390
400
38
Karttunnen
R.
Breese
E.J.
Walker-Smith
J.A.
MacDonald
T.T.
Decreased mucosal interleukin-4 (IL-4) production in gut inflammation
J Clin Pathol
 
47
1994
1015
1018
39
MacDonald
T.T.
Hutchings
P.
Choy
M.Y.
Murch
S.
Cooke
A.
Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine
Clin Exp Immunol
 
81
1990
301
305
40
Reimund
J.M.
Wittersheim
C.
Dumont
S.
Muller
C.D.
Baumann
R.
Poindron
P.
et al
Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease
J Clin Immunol
 
16
1996
144
150
41
Wang
Y.D.
Mao
J.W.
Expression of matrix metalloproteinase-1 and tumor necrosis factor-alpha in ulcerative colitis
World J Gastroenterol
 
13
2007
5926
5932
42
Balding
J.
Livingstone
W.J.
Conroy
J.
Mynett-Johnson
L.
Weir
D.G.
Mahmud
N.
et al
Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms
Mediators Inflamm
 
13
2004
181
187
Figure 1

Correlation of IL-8 concentration and endoscopic grade of inflammation.

Figure 1

Correlation of IL-8 concentration and endoscopic grade of inflammation.

Figure 2

Correlation of IL-8 concentration and histological grade of inflammation.

Figure 2

Correlation of IL-8 concentration and histological grade of inflammation.

Figure 3

Correlation of TGFβ concentration and endoscopic grade of inflammation.

Figure 3

Correlation of TGFβ concentration and endoscopic grade of inflammation.

Figure 4

Correlation of TGFβ concentration and histological score of inflammation.

Figure 4

Correlation of TGFβ concentration and histological score of inflammation.

Table 1

Characteristics of active colitis patients and matched healthy controls, and patients with paired samples (inflamed and non-inflamed).

 Active colitis (n69) Controls (n69) Active colitis ‘paired’ (n54) 
Sex    
Male 35 35 26 
Female 34 34 28 
Mean age ± SEM (years) 45.6 ± 1.6 46.5 ± 1.6 44.4 ± 1.8 
Mean CRP ± SEM (mg/l) 11.4 ± 3.1 7.6 ± 1.8 7.0 ± 1.1 
 Active colitis (n69) Controls (n69) Active colitis ‘paired’ (n54) 
Sex    
Male 35 35 26 
Female 34 34 28 
Mean age ± SEM (years) 45.6 ± 1.6 46.5 ± 1.6 44.4 ± 1.8 
Mean CRP ± SEM (mg/l) 11.4 ± 3.1 7.6 ± 1.8 7.0 ± 1.1 
 Active colitis (n69) Active colitis-‘paired’ (n54) 
Disease distribution (%)   
Proctitis 27 (56.3) 32 (59.3) 
Distal 15 (31.3) 16 (29.6) 
Left sided 3 (6.2) 3 (5.5) 
Extensive 3 (6.2) 3 (5.5) 
Unknown 21 
Disease Longevity (yr)   
0–10 44 37 
11–20 13 
> 20 11 
Unknown 
Current drug history (%)   
5-ASA 46 (66) 32 (60) 
Corticosteroids 11 (16) 14 (26) 
Thiopurines 14 (20) 8 (15) 
Methotrexate 3 (4) 1 (2) 
Cyclosporine 1 (1) 1 (2) 
Disease activity   
Mean UCDAIa 5.4 ± 0.4 4.8 ± 0.4 
Endoscopic score (%)b   
35 (50.7) 36 (66.7) 
22 (31.9) 13 (24.1) 
12 (17.4) 5 (9.3) 
Histological score (%)c   
6 (8.6) 8 (14.8) 
27 (39.2) 24 (44.4) 
15 (21.8) 11 (20.4) 
11 (16.0) 8 (14.8) 
10 (14.4) 3 (5.6) 
Smoking history (%) 5 (7.2) 6 (11.1) 
 Active colitis (n69) Active colitis-‘paired’ (n54) 
Disease distribution (%)   
Proctitis 27 (56.3) 32 (59.3) 
Distal 15 (31.3) 16 (29.6) 
Left sided 3 (6.2) 3 (5.5) 
Extensive 3 (6.2) 3 (5.5) 
Unknown 21 
Disease Longevity (yr)   
0–10 44 37 
11–20 13 
> 20 11 
Unknown 
Current drug history (%)   
5-ASA 46 (66) 32 (60) 
Corticosteroids 11 (16) 14 (26) 
Thiopurines 14 (20) 8 (15) 
Methotrexate 3 (4) 1 (2) 
Cyclosporine 1 (1) 1 (2) 
Disease activity   
Mean UCDAIa 5.4 ± 0.4 4.8 ± 0.4 
Endoscopic score (%)b   
35 (50.7) 36 (66.7) 
22 (31.9) 13 (24.1) 
12 (17.4) 5 (9.3) 
Histological score (%)c   
6 (8.6) 8 (14.8) 
27 (39.2) 24 (44.4) 
15 (21.8) 11 (20.4) 
11 (16.0) 8 (14.8) 
10 (14.4) 3 (5.6) 
Smoking history (%) 5 (7.2) 6 (11.1) 

a UCDAI-ulcerative colitis disease activity index16 (Daily stool frequency [0 = normal; 1 = 1-2 above normal; 2 = 3-4 above normal; 3 = > 4 above normal] + Rectal bleeding [0 = none; 1 = streaks of blood; 2 = obvious blood; 3 = mostly blood] + Sutherland score [see below] + Physicians global assessment [0 = normal; 1 = mild; 2 = moderate; 3 = severe]).

b Sutherland endoscopic scoring tool17 (0 = normal; 1 = mild friability; 2 = moderate friability, bleeding on contact; 3 = exudation, spontaneous haemorrhage).

c Gomes Histological score15 (0 = normal, 1 = mild oedema and inflammation in lamina propria; 2 = crypt abscess formation and inflammation in lamina propria; 3 = more severe inflammation with destructive crypt abscesses ± granulomata; 4 = more severe inflammation with active ulceration).

Table 2

Comparison of mucosal cytokine profiles in UC patients, ‘paired’ inflamed and non-inflamed mucosa (median ± inter-quartile range).

 Paired  
Inflamed (n54) Non-inflamed (n54) Inflamed/non-inflamed p-Value* 
IFNγ 1.01 (0.83–1.25) 1.17 (0.97–1.44) 0.87 (0.73-0.98) < 0.0001 
IL-4 1.49 (0.70–2.47) 1.86 (0.70–3.21) 0.91 (0.67-1.1) < 0.01 
IL-8 0.66 (0.40–0.86) 0.47 (0.34–0.59) 1.38 (0.95–1.86) 0.001 
IL-17 0.53 (0.27–2.69) 0.70 (0.39–3.64) 0.74 (0.53–1.05) < 0.01 
TNFα 1.50 (1.19–1.90) 1.71 (1.09–1.98) 0.91 (0.70–1.20) 0.572 
IL-10 4.73 (2.43–5.90) 5.95 (3.61–7.06) 0.81 (0.57–1.08) 0.011 
TGFβ 44.4 (0.0–87.0) 75.3 (23.5–145.7) 0.30 (0.01–0.82) 0.01 
 Paired  
Inflamed (n54) Non-inflamed (n54) Inflamed/non-inflamed p-Value* 
IFNγ 1.01 (0.83–1.25) 1.17 (0.97–1.44) 0.87 (0.73-0.98) < 0.0001 
IL-4 1.49 (0.70–2.47) 1.86 (0.70–3.21) 0.91 (0.67-1.1) < 0.01 
IL-8 0.66 (0.40–0.86) 0.47 (0.34–0.59) 1.38 (0.95–1.86) 0.001 
IL-17 0.53 (0.27–2.69) 0.70 (0.39–3.64) 0.74 (0.53–1.05) < 0.01 
TNFα 1.50 (1.19–1.90) 1.71 (1.09–1.98) 0.91 (0.70–1.20) 0.572 
IL-10 4.73 (2.43–5.90) 5.95 (3.61–7.06) 0.81 (0.57–1.08) 0.011 
TGFβ 44.4 (0.0–87.0) 75.3 (23.5–145.7) 0.30 (0.01–0.82) 0.01 

* Wilcoxon signed rank pair analysis.

Table 3

Comparison of mucosal cytokine profiles in UC patients (inflamed mucosa) compared with age–sex matched controls (median ± inter-quartile range).

 Matched  
Inactive (n69) Control (n69) p-Value* 
IFNγ 0.99 (0.80–1.21) 1.17 (0.96–1.38) < 0.01 
IL-4 1.46 (0.53–2.43) 1.16 (0.79–2.45) = 0.863 
IL-8 0.67 (0.42–0.95) 0.44 (0.30–0.57) < 0.0001 
IL-17 0.59 (0.27–2.73) 0.51 (0.31–2.83) = 0.979 
TNFα 1.45 (1.10–1.85) 1.55 (1.22–2.09) = 0.325 
IL-10 4.78 (2.44–5.90) 5.72 (1.51–6.92) = 0.368 
TGFβ 57.7 (38.7–120) 107 (78–208) < 0.0001 
 Matched  
Inactive (n69) Control (n69) p-Value* 
IFNγ 0.99 (0.80–1.21) 1.17 (0.96–1.38) < 0.01 
IL-4 1.46 (0.53–2.43) 1.16 (0.79–2.45) = 0.863 
IL-8 0.67 (0.42–0.95) 0.44 (0.30–0.57) < 0.0001 
IL-17 0.59 (0.27–2.73) 0.51 (0.31–2.83) = 0.979 
TNFα 1.45 (1.10–1.85) 1.55 (1.22–2.09) = 0.325 
IL-10 4.78 (2.44–5.90) 5.72 (1.51–6.92) = 0.368 
TGFβ 57.7 (38.7–120) 107 (78–208) < 0.0001 

* Independent samples Mann–Whitney U test.

Table 4

Comparison of mucosal cytokine profiles in UC patients (non-inflamed) compared with age–sex matched controls (median ± inter-quartile range).

 Matched  
Inactive (n69) Control (n69) p-Value* 
IFNγ 1.19 (0.98–1.44) 1.17 (0.96–1.38) = 0.700 
IL-4 1.93 (0.64–3.17) 1.16 (0.79–2.45) = 0.025 
IL-8 0.50 (0.35–0.64) 0.44 (0.30–0.57) = 0.174 
IL-17 0.77 (0.40–3.52) 0.51 (0.31–2.83) = 0.114 
TNFα 1.66 (1.08–1.97) 1.55 (1.22–2.09) = 0.228 
IL-10 5.95 (3.84–7.05) 5.72 (1.51–6.92) = 0.651 
TGFβ 75.3 (23.8–146) 107 (78–208) = 0.765 
 Matched  
Inactive (n69) Control (n69) p-Value* 
IFNγ 1.19 (0.98–1.44) 1.17 (0.96–1.38) = 0.700 
IL-4 1.93 (0.64–3.17) 1.16 (0.79–2.45) = 0.025 
IL-8 0.50 (0.35–0.64) 0.44 (0.30–0.57) = 0.174 
IL-17 0.77 (0.40–3.52) 0.51 (0.31–2.83) = 0.114 
TNFα 1.66 (1.08–1.97) 1.55 (1.22–2.09) = 0.228 
IL-10 5.95 (3.84–7.05) 5.72 (1.51–6.92) = 0.651 
TGFβ 75.3 (23.8–146) 107 (78–208) = 0.765 

* Independent Samples Mann–Whitney U Test.

Table 5

Correlations of cytokine mucosal profiles (inflamed mucosa) and endoscopic score in UC patients.

 Spearman correlation (n69) 
IFNγ rs = − 0.321* 
IL-4 rs = − 0.022 
IL-8 rs = 0.481* 
IL-17 rs = − 0.048 
TNFα rs= − 0.112 
IL-10 rs = − 0.003 
TGFβ rs = − 0.462* 
 Spearman correlation (n69) 
IFNγ rs = − 0.321* 
IL-4 rs = − 0.022 
IL-8 rs = 0.481* 
IL-17 rs = − 0.048 
TNFα rs= − 0.112 
IL-10 rs = − 0.003 
TGFβ rs = − 0.462* 

* Spearman's correlation, p < 0.01.

Table 6

Correlations of cytokine mucosal profiles (inflamed mucosa) and histological score in UC patients.

 Spearman correlation (n69) 
IFNγ rs = − 0.241* 
IL-4 rs = − 0.037 
IL-8 rs = 0.460** 
IL-17 rs = − 0.169 
TNFα rs = − 0.212 
IL-10 rs = 0.114 
TGFβ rs = − 0.460** 
 Spearman correlation (n69) 
IFNγ rs = − 0.241* 
IL-4 rs = − 0.037 
IL-8 rs = 0.460** 
IL-17 rs = − 0.169 
TNFα rs = − 0.212 
IL-10 rs = 0.114 
TGFβ rs = − 0.460** 

* Spearman's correlation, p < 0.05.

** Spearman's correlation, p < 0.01.

Table 7

Comparison of mucosal cytokine profiles in 5-ASA and corticosteroid naive UC patients, compared with age sex matched controls (median ± inter-quartile range) and correlations to endoscopic score.

 Matched  
Inflamed (18) Control (67) p-Valuea Correlation with endoscopic score 
IFNγ 0.99 (0.85–1.35) 1.17 (0.96–1.38) = 0.309 rs = − 0.141 
IL-4 2.16 (1.49–3.37) 1.16 (0.79–2.45) = 0.087 rs = 0.186 
IL-8 0.61 (0.40–0.88) 0.44 (0.30–0.57) < 0.005 rs = 0.333* 
IL-17 2.06 (0.51–3.17) 0.51 (0.31–2.83) = 0.062 rs= − 0.182 
TNFα 1.43 (1.04–1.72) 1.55 (1.22–2.09) = 0.277 rs = − 0.130 
IL-10 3.98 (2.52–5.86) 5.72 (1.51–6.92) = 0.467 rs = − 0.071 
TGFβ 54.1 (41.0–129) 107 (78–208)b < 0.005 rs = − 0.373* 
 Matched  
Inflamed (18) Control (67) p-Valuea Correlation with endoscopic score 
IFNγ 0.99 (0.85–1.35) 1.17 (0.96–1.38) = 0.309 rs = − 0.141 
IL-4 2.16 (1.49–3.37) 1.16 (0.79–2.45) = 0.087 rs = 0.186 
IL-8 0.61 (0.40–0.88) 0.44 (0.30–0.57) < 0.005 rs = 0.333* 
IL-17 2.06 (0.51–3.17) 0.51 (0.31–2.83) = 0.062 rs= − 0.182 
TNFα 1.43 (1.04–1.72) 1.55 (1.22–2.09) = 0.277 rs = − 0.130 
IL-10 3.98 (2.52–5.86) 5.72 (1.51–6.92) = 0.467 rs = − 0.071 
TGFβ 54.1 (41.0–129) 107 (78–208)b < 0.005 rs = − 0.373* 

* Spearman's correlation, p < 0.01.

a Mann–Whitney U test.

b control group for TGFβ analysis 52/67 results due to undetectable values in control data set.

Table 8

Comparison of mucosal cytokine profiles in UC patients with age–sex matched controls: subgroup analysis of endoscopically determined severely inflamed mucosa (median ± inter-quartile range).

 Matched  
Endoscopically severe (12) Control (69) p-Valuea 
IFNγ 0.89 (0.72–1.00) 1.17 (0.96–1.38) < 0.005 
IL-4 1.20 (0.53–2.16) 1.16 (0.79–2.45) = 0.528 
IL-8 1.17 (0.72–1.60) 0.44 (0.30–0.57) < 0.001 
IL-17 0.53 (0.23–2.68) 0.51 (0.31–2.83) = 0.599 
TNFα 1.38 (0.90–1.58) 1.55 (1.22–2.09) = 0.123 
IL-10 5.48 (4.50–5.85) 5.72 (1.51–6.92) = 0.799 
TGFβ 35.66 (13.26–71.71) 107 (78–208)b < 0.001 
 Matched  
Endoscopically severe (12) Control (69) p-Valuea 
IFNγ 0.89 (0.72–1.00) 1.17 (0.96–1.38) < 0.005 
IL-4 1.20 (0.53–2.16) 1.16 (0.79–2.45) = 0.528 
IL-8 1.17 (0.72–1.60) 0.44 (0.30–0.57) < 0.001 
IL-17 0.53 (0.23–2.68) 0.51 (0.31–2.83) = 0.599 
TNFα 1.38 (0.90–1.58) 1.55 (1.22–2.09) = 0.123 
IL-10 5.48 (4.50–5.85) 5.72 (1.51–6.92) = 0.799 
TGFβ 35.66 (13.26–71.71) 107 (78–208)b < 0.001 

a Mann–Whitney U test.

b control group for TGFβ analysis 54/69 results due to undetectable values in control data set.

Table 9

Comparison of mucosal cytokine profiles in UC patients with age–sex matched controls: subgroup analysis of histologically determined severely inflamed mucosa (median ± inter-quartile range).

 Matched  
Histologically severe (10) Control (69) p-Valuea 
IFNγ 1.03 (0.73–1.14) 1.17 (0.96–1.38) = 0.100 
IL-4 1.61 (0.46–3.77) 1.16 (0.79–2.45) = 0.740 
IL-8 1.17 (0.47–1.54) 0.44 (0.30–0.57) < 0.001 
IL-17 1.21 (0.21–3.04) 0.51 (0.31–2.83) = 0.622 
TNFα 1.43 (0.85–2.33) 1.55 (1.22–2.09) = 0.452 
IL-10 5.48 (4.07–6.75) 5.72 (1.51–6.92) = 0.870 
TGFβ 42.51 (30.07–73.87) 107 (78–208)b < 0.01 
 Matched  
Histologically severe (10) Control (69) p-Valuea 
IFNγ 1.03 (0.73–1.14) 1.17 (0.96–1.38) = 0.100 
IL-4 1.61 (0.46–3.77) 1.16 (0.79–2.45) = 0.740 
IL-8 1.17 (0.47–1.54) 0.44 (0.30–0.57) < 0.001 
IL-17 1.21 (0.21–3.04) 0.51 (0.31–2.83) = 0.622 
TNFα 1.43 (0.85–2.33) 1.55 (1.22–2.09) = 0.452 
IL-10 5.48 (4.07–6.75) 5.72 (1.51–6.92) = 0.870 
TGFβ 42.51 (30.07–73.87) 107 (78–208)b < 0.01 

a Mann–Whitney U test.

b control group for TGFβ analysis 54/69 results due to undetectable values in control data set.